Aki Hoji
Immunology and Microbiology · Indiana University
Publications
52
Citations
1,469
Est. group size
~1
Recurring co-author estimate
Active years
27
Publishing since 2000
Aki Hoji studies how the immune system, especially CD8+ T cells (a type of white blood cell that kills infected or abnormal cells), responds in the context of cancer, viral infections, and organ transplants. Recent work includes testing peptide-based vaccines to trigger immune responses against brain tumors (low-grade glioma) and identifying immune markers that predict rejection or dysfunction in lung transplants. The research combines clinical samples with molecular profiling of gene and protein activity.
Publication activity has been fairly steady over the decade with a large spike in 2023 (partly from supplementary data files of a single study), then returning to low counts.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Supplementary Table 2 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Figure 1 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Figure 2 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Figure 2 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Figure 1 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Table 1 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Table 2 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Data from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Data from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Supplementary Table 1 from Induction of Robust Type-I CD8<sup>+</sup> T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
2023
- Editorial: A new perspective of human CD8+ T cells with respect to their biology, protective and pathogenic role in anti-viral and tumor responses
Frontiers in Immunology · 2023
- Cross-Regulation of F-Box Protein FBXL2 with T-bet and TNF-α during Acute and Chronic Lung Allograft Rejection
The Journal of Immunology · 2022
- Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction
American Journal of Transplantation · 2020
- Cigarette smoke exposure enhances transforming acidic coiled-coil–containing protein 2 turnover and thereby promotes emphysema
JCI Insight · 2020
- Transcriptome Analysis of Airway Brushes in Lung Transplant Recipients with and without Chronic Lung Allograft Dysfunction
The Journal of Heart and Lung Transplantation · 2020
- The Journal of Immunology×5
- The Journal of Heart and Lung Transplantation×3
- Frontiers in Allergy×2
- American Journal of Respiratory and Critical Care Medicine×1
- American Journal of Transplantation×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile